Sharekhan

Akums Drugs and Pharmaceuticals Ltd

Fri 22/05/2026,15:50:56 | NSE : AKUMS

₹ 520.05-1.30 (-0.25%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 523.50

Previous Close

₹ 521.35

Volume

221535

Mkt Cap ( Rs. Cr)

₹8185.27

High

₹ 525.45

Low

₹ 516.60

52 Week High

₹ 622.95

52 Week Low

₹ 409.30

Book Value Per Share

₹ 204.41

Dividend Yield

0.19

Face Value

₹ 2.00

What’s Your Call?

Collective community sentiment on Akums Drugs and Pharmaceuticals Ltd

Your Vote -

Buy

76.32%

Hold

13.16%

Sell

10.53%

76.32%

38 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

100%

Sell Order Quantity

0%

Bid Price

Qty

520.05

16

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

16

Bid Price

Qty

0.00

0

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

0

Option Chain

Analyzes market sentiment, predicts Akums Drugs and Pharmaceuticals Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Akums Drugs&Pharma. - Receipt Of Assessment Order(S) By Certain Subsidiaries From Income Tax Department

    22 May 2026, 11:34AM Receipt of Assessment Order(s) by certain subsidiaries from Income Tax Department
  • Akums Drugs&Pharma. - Action(s) initiated or orders passed

    22 May 2026, 11:30AM Receipt of Assessment Order(s) by certain subsidiaries from Income Tax Department
  • Akums Drugs&Pharma. - Analysts/Institutional Investor Meet/Con. Call Updates

    21 May 2026, 12:12PM Transcript of Investors/Analysts Conference Call held for un-audited financial results of Q4 FY 2025-26 and audited financial results for FY 2025-26
  • Akums Drugs&Pharma. - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

    21 May 2026, 12:18PM Transcript on investors/analysts conference call held for un-audited financial results of Q4 FY 2025-26 and audited financial results for FY 2025-26
  • Akums Drugs&Pharma. - Receipt Of Assessment Order(S) From Income Tax Department

    20 May 2026, 7:09PM Receipt of Assessment Order(s) from Income Tax Department
  • Akums Drugs&Pharma. - Action(s) taken or orders passed

    20 May 2026, 7:06PM Akums Drugs and Pharmaceuticals Limited has informed the Exchange about receipt of Assessment Order(s) from Income Tax Department
  • Akums Drugs&Pharma. - Analysts/Institutional Investor Meet/Con. Call Updates

    18 May 2026, 4:57PM Link of Audio Recording of Investor/Analysts Conference Call
  • Akums Drugs&Pharma. - Disruption of Operations

    18 May 2026, 12:07PM Update on Disruption of Operations
  • Akums Drugs&Pharma. - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

    18 May 2026, 5:03PM Link of Audio Recording of Investor/Analyst Conference Call
  • Akums Pharma restarts Uttarakhand operations at full capacity

    18 May 2026, 12:17PM Akums Drugs and Pharmaceuticals has resumed full-scale manufacturing operations at its affected facilities in Uttarakhand from May 18, 2026, following
  • Akums Drugs&Pharma. - Update On Disruption In Operations At Some Of The Manufacturing Sites At Haridwar

    18 May 2026, 12:11PM Update on Disruption in Operations at come of the Manufacturing Sites at Haridwar
  • Akums Drugs&Pharma. - Update On Disruption In Operations At Some Of The Manufacturing Sites At Haridwar

    16 May 2026, 2:36PM Update on Disruption in Operations at some of the manufacturing sites at Haridwar
  • Akums Drugs&Pharma. - Disruption of Operations

    16 May 2026, 2:32PM Update on Disruption in Operations at some of the manufacturing sites at Haridwar
  • Akums Drugs&Pharma. - Copy of Newspaper Publication

    15 May 2026, 4:43PM Intimation regarding Newspaper Publication
  • Akums Drugs&Pharma. - Investor Presentation

    14 May 2026, 5:36PM Akums Drugs and Pharmaceuticals Limited has informed the Exchange about Investor Presentation
  • Akums Drugs&Pharma. - Monitoring Agency Report

    14 May 2026, 5:17PM Monitoring Agency Report for the quarter ended 31st March, 2026
  • Akums Drugs&Pharma. - Press Release

    14 May 2026, 4:33PM Akums Drugs and Pharmaceuticals Limited has informed the Exchange regarding a press release dated May 14, 2026, titled ""Press Release"".
  • Akums Drugs&Pharma. - General Updates

    14 May 2026, 4:20PM Intimation of Disruption in Operations at some of the manufacturing sites at Haridwar
  • Akums Drugs&Pharma. - Record Date

    14 May 2026, 2:27PM Akums Drugs and Pharmaceuticals Limited has informed the Exchange that Record date for the purpose of Dividend is 03-Jul-2026.
  • Akums Drugs&Pharma. - Change in Management

    14 May 2026, 2:13PM Changes in Senior Management Personnel
  • Akums Drugs&Pharma. - Change in Management

    14 May 2026, 2:02PM Appointment of Internal Auditors for the FY 2026-27
  • Akums Drugs&Pharma. - Change in Management

    14 May 2026, 2:00PM Re-appointment of Cost Auditors for the FY 2026-27
  • Akums Drugs&Pharma. - General Updates

    14 May 2026, 1:54PM Financial Results for the quarter and year ended 31st March, 2026
  • Akums Drugs&Pharma. - General Updates

    14 May 2026, 1:43PM Akums Drugs and Pharmaceuticals Limited has informed the Exchange about Recommendation of final cum special dividend
  • Akums Drugs&Pharma. - Outcome of Board Meeting

    14 May 2026, 1:34PM Akums Drugs and Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
  • Akums Drugs&Pharma. - Announcement under Regulation 30 (LODR)-Investor Presentation

    14 May 2026, 5:32PM Investor Presentation
  • Akums Drugs&Pharma. - Announcement under Regulation 30 (LODR)-Monitoring Agency Report

    14 May 2026, 5:20PM Monitoring Agency Report for the quarter ended on 31st March, 2026
  • Akums Drugs&Pharma. - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    14 May 2026, 4:35PM Press Release
  • Akums Drugs&Pharma. - Intimation Of Disruption In Operations At Some Of The Manufacturing Sites At Haridwar

    14 May 2026, 4:23PM Intimation of Disruption in Operations at some of the manufacturing sites at Haridwar
  • Akums Drugs&Pharma. - Corporate Action-Board approves Dividend

    14 May 2026, 2:18PM The Board has fixed Friday, July 03, 2026, as the \Record Date\ to ascertain the eligibility of the shareholders for the payment of final cum special
  • Akums Drugs&Pharma. - Announcement under Regulation 30 (LODR)-Change in Management

    14 May 2026, 2:10PM Changes in Senior Management Personnel
  • Akums Drugs&Pharma. - Announcement under Regulation 30 (LODR)-Change in Management

    14 May 2026, 2:07PM Appointment of Internal Auditors for the FY 2026-27
  • Akums Drugs&Pharma. - Announcement under Regulation 30 (LODR)-Change in Management

    14 May 2026, 2:05PM Re-appointment of Cost Auditors for the FY 2026-27
  • Akums Drugs&Pharma. - Financial Results For The Quarter And Year Ended 31St March, 2026

    14 May 2026, 1:52PM Financial Results for the quarter and year ended 31st March, 2026
  • Akums Drugs&Pharma. Q4 net profit down 44.91% at Rs 15.20 cr

    14 May 2026, 1:50PM The company reported standalone net profit of Rs 15.20 crore for the quarter ended March 31, 2026 as compared to Rs 27.59 crore in the same period las
  • Akums Drugs&Pharma. - Recommendation Of Final Cum Special Dividend

    14 May 2026, 1:46PM Recommendation of Final cum Special Dividend
  • Akums Drugs&Pharma. - Board Meeting Outcome for Outcome Of Board Meeting For Financial Results

    14 May 2026, 1:39PM Outcome of Board meeting for Financial Results
  • Akums Drugs&Pharma. - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    12 May 2026, 8:50PM Intimation of Schedule of the Analysts Conference Call for Q4 results and audited financials for FY2026
  • Akums Drugs&Pharma. - Analysts/Institutional Investor Meet/Con. Call Updates

    12 May 2026, 8:46PM Akums Drugs and Pharmaceuticals Limited has informed the Exchange about Schedule of meet
  • Akums Drugs&Pharma. - Board Meeting Intimation for Board Meeting Intimation

    11 May 2026, 11:10PM Akums Drugs And Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/05/2026 ,inter alia,
  • Akums Drugs&Pharma. - ESG Rating

    8 May 2026, 2:51PM Intimation of ESG Rating
  • Akums Drugs&Pharma. - General Updates

    8 May 2026, 2:48PM ESG Rating
  • Akums Drugs&Pharma. - General Updates

    29 Apr 2026, 6:11PM Akums Drugs and Pharmaceuticals Limited has informed the Exchange about General Updates
  • Akums Drugs&Pharma. - Execution Of Lease Deed

    29 Apr 2026, 5:49PM Pure and Cure Healthcare Private Limited, a wholly-owned subsidiary of the Company has executed a lease deed to purchase an Industrial plot.
  • Akums Drugs&Pharma. - Credit Rating

    11 Apr 2026, 5:41PM Akums Drugs and Pharmaceuticals Limited has informed the Exchange about Credit Rating
  • Akums Drugs&Pharma. - Announcement under Regulation 30 (LODR)-Credit Rating

    11 Apr 2026, 5:36PM Intimation of reaffirmed/ new credit rating under Reg 30 of SEBI (LODR) Regulations, 2015
  • Akums Drugs&Pharma. has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2026

    7 Apr 2026, 6:00PM As of March 2026, 75.26% is owned by Indian Promoters, 22.01% by Public and 2.73% by Non Promoters-Non Public. <p align=justify> Institutional holds 1
  • Akums Drugs&Pharma. - Certificate under SEBI (Depositories and Participants) Regulations, 2018

    4 Apr 2026, 1:02PM Akums Drugs and Pharmaceuticals Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
  • Akums Drugs&Pharma. - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    4 Apr 2026, 1:04PM Compliance Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018
  • Akums Drugs&Pharma. - Disclosure under SEBI Takeover Regulations

    2 Apr 2026, 7:31PM Akums Drugs and Pharmaceuticals Limitedÿhas Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board
  • Akums Drugs&Pharma. - Trading Window

    23 Mar 2026, 12:56PM Akums Drugs and Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Tradin
  • Akums Drugs&Pharma. - Analysts/Institutional Investor Meet/Con. Call Updates

    26 Feb 2026, 12:50PM Akums Drugs and Pharmaceuticals Limited has informed the Exchange about Schedule of meet
  • Akums Drugs&Pharma. - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    26 Feb 2026, 12:48PM Bharat Connect Conference

Key fundamentals

Evaluate the intrinsic value of Akums Drugs and Pharmaceuticals Ltd stock 

Name March-26 March-25 March-24
Assets 2441.119 2309.177 370.164
Liabilities 2441.119 2309.177 370.164
Equity 30.621 30.621 28.613
Gross Profit 97.46 138.499 -126.658
Net Profit 111.64 160.998 -165.451
Cash From Operating Activities -1.994 91.002 247.907
NPM(%) 8.27 12.27 -11.45
Revenue 1348.736 1311.784 1444.119
Expenses 1251.276 1173.285 1570.777
ROE(%) 3.47 5 -5.14

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day
1 50 0.19 516.95

Peers

Other companies within the same industry or sector that are comparable to Akums Drugs and Pharmaceuticals Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 705.80 -0.07 0.00 296.97 -26.19 0.71
Lotus Eye Hospital and Institute Ltd 109.19 1.26 352.23 1082.14 3.55 0.00
Vaishali Pharma Ltd 7.00 0.14 0.00 6788.60 3.13 0.00
Astec Lifesciences Ltd 771.80 4.77 0.00 1020.48 -363.15 0.00

Company Info

Our Company was incorporated as a public limited company under the Companies Act, 1956 as `Akums Drugs and Pharmaceuticals Limited', pursuant to a certificate of incorporation dated April 19, 2004 issued by the RoC. Our Company received a certificate for commencement of business issued by the RoC dated May 13, 2004.Major Events and Milestones:2004-Incorporation of the Company-Established first plant for oral dosage commissioned at 19, 20, 21, sector 6A, Haridwar, Uttarakhand2007-Established dedicated manufacturing site for oral liquid dosage at 22, Sector 6A, Sidcul, Haridwar, Uttarakhand and sterile products at 2,3,4,5, Sector 6B, SIDCUL, Haridwar, Uttarakhand2009-Incorporated Maxcure Nutravedics Limited to venture into nutraceuticals2010-Dedicated a facility for hormones at 48, Sector 6A, SIDCUL, Haridwar, Uttarakhand-Dedicated a facility for cosmetics and dermatology at 47, Sector 6A, SIDCUL, Haridwar, Uttarakhand-Incorporated Akumentis Healthcare Limited to venture into branded formulations2011-Innovated bi-layered sustained release tablets for the first time2012-Acquired Pure and Cure Healthcare Private Limited to expand capacity and capabilities2013-Innovated tablet-in-tablet sustained release tablets for the first time-Acquired Malik Lifesciences Private Limited manufacturing sites to expand capacity and capabilities-Expanded into the African market2015-Expanded into the Asian market-Established research and development laboratory in Mumbai, Maharashtra to venture into regulated market2016-Maxcure Nutravedics Limited received US-NSF certification2019-Investment by Ruby QC Investment Holdings Pte. Ltd. in our Company to become a minority shareholder2021-Acquired Parabolic Drugs to form Akums Lifesciences Limited and ventured into APIs-Acquisition of a facility at Kotdwar, Uttarakhand by Akums Healthcare Limited2022-Plant at 19, 20, 21, Sector 6A, SIDCUL, Haridwar, Uttarakhand and plant at 2, 3, 4,5, Sector 6B, SIDCUL, Haridwar, Uttarakhand accredited European Union-Good Manufacturing Practices, qualifying for exports to European markets-Acquisition of a facility in Haridwar, Uttarakhand by Akums Healthcare Limited and a facility in Baddi, Himachal Pradesh by Pure and Cure Healthcare Private Limited2023-Acquisition of another facility in Baddi, Himachal Pradesh by Pure and Cure Healthcare Private Limited-Merger of Akums Lifesciences Limited with Pure and Cure Healthcare Private Limited 2024 -The Company has informed to exchange regarding new product launches.

Our Company was incorporated as a public limited company under the Companies Act, 1956 as `Akums Drugs and Pharmaceuticals Limited', pursuant to a certificate of incorporation dated April 19, 2004 issued by the RoC. Our Company received a certificate for commencement of business issued by the RoC dated May 13, 2004.Major Events and Milestones:2004-Incorporation of the Company-Established first plant for oral dosage commissioned at 19, 20, 21, sector 6A, Haridwar, Uttarakhand2007-Established dedicated manufacturing site for oral liquid dosage at 22, Sector 6A, Sidcul, Haridwar, Uttarakhand and sterile products at 2,3,4,5, Sector 6B, SIDCUL, Haridwar, Uttarakhand2009-Incorporated Maxcure Nutravedics Limited to venture into nutraceuticals2010-Dedicated a facility for hormones at 48, Sector 6A, SIDCUL, Haridwar, Uttarakhand-Dedicated a facility for cosmetics and dermatology at 47, Sector 6A, SIDCUL, Haridwar, Uttarakhand-Incorporated Akumentis Healthcare Limited to venture into branded formulations2011-Innovated bi-layered sustained release tablets for the first time2012-Acquired Pure and Cure Healthcare Private Limited to expand capacity and capabilities2013-Innovated tablet-in-tablet sustained release tablets for the first time-Acquired Malik Lifesciences Private Limited manufacturing sites to expand capacity and capabilities-Expanded into the African market2015-Expanded into the Asian market-Established research and development laboratory in Mumbai, Maharashtra to venture into regulated market2016-Maxcure Nutravedics Limited received US-NSF certification2019-Investment by Ruby QC Investment Holdings Pte. Ltd. in our Company to become a minority shareholder2021-Acquired Parabolic Drugs to form Akums Lifesciences Limited and ventured into APIs-Acquisition of a facility at Kotdwar, Uttarakhand by Akums Healthcare Limited2022-Plant at 19, 20, 21, Sector 6A, SIDCUL, Haridwar, Uttarakhand and plant at 2, 3, 4,5, Sector 6B, SIDCUL, Haridwar, Uttarakhand accredited European Union-Good Manufacturing Practices, qualifying for exports to European markets-Acquisition of a facility in Haridwar, Uttarakhand by Akums Healthcare Limited and a facility in Baddi, Himachal Pradesh by Pure and Cure Healthcare Private Limited2023-Acquisition of another facility in Baddi, Himachal Pradesh by Pure and Cure Healthcare Private Limited-Merger of Akums Lifesciences Limited with Pure and Cure Healthcare Private Limited 2024 -The Company has informed to exchange regarding new product launches.

Parent Organisation

Akums Drugs & Pharmaceuticals Ltd.

Founded

19/04/2004

Managing Director

Mr.Sanjeev Jain

NSE Symbol

AKUMSEQ

FAQ

OPEN FREE* DEMAT ACCOUNT